117738-77-9 Usage
Description
2-Chloro-4-cyanobenzoic acid, a chemical compound with the molecular formula C8H4ClNO2, is a white to yellow crystalline powder. It is insoluble in water but soluble in organic solvents. This versatile and important chemical in the industry is characterized by its reactivity and functional groups, making it a valuable building block for the production of various organic compounds.
Uses
Used in Pharmaceutical and Agrochemical Industries:
2-Chloro-4-cyanobenzoic acid is used as a key intermediate in the synthesis of pharmaceuticals and agrochemicals. Its unique structure and reactivity contribute to the development of new and effective drugs and pesticides.
Used in Research and Development:
2-CHLORO-4-CYANOBENZOIC ACID is utilized in research and development applications, where its properties are studied and explored for potential uses in various fields, including material science and chemical engineering.
Used in Dye and Pigment Manufacturing:
2-Chloro-4-cyanobenzoic acid is employed as an intermediate in the manufacture of dyes and pigments, contributing to the production of a wide range of colorants used in various industries such as textiles, plastics, and printing inks.
Check Digit Verification of cas no
The CAS Registry Mumber 117738-77-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,1,7,7,3 and 8 respectively; the second part has 2 digits, 7 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 117738-77:
(8*1)+(7*1)+(6*7)+(5*7)+(4*3)+(3*8)+(2*7)+(1*7)=149
149 % 10 = 9
So 117738-77-9 is a valid CAS Registry Number.
117738-77-9Relevant articles and documents
NOVEL TRIFLUOROMETHYL-OXADIAZOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE
-
, (2013/03/26)
The invention relates to novel trifluoromethyl-oxadiazole derivatives of formula (I), and pharmaceutically acceptable salts thereof, (I) in which all of the variables are as defined in the specification, pharmaceutical compositions thereof, pharmaceutical combinations thereof, and their use as medicaments, particularly for the treatment of neurodegeneration, muscle atrophy or metabolic syndrome via inhibition of HDAC4.
Piperazines as oxytocin agonists
-
Page/Page column 9-10, (2010/02/11)
Disclosed are novel compounds according to general formula I, which have shown OT agonist activity.
benzamide derivatives as oxytocin agonists and vasopressin antagonists
-
Page 24, (2010/02/08)
Novel compounds according to general formula 1, wherein G1 is NR5R6 or a fused polycyclic group that are specific OT receptor agonists and/or Via receptor antagonists. Pharmaceutical compositions comprising such compounds are useful in the treatment of, inter alia, primary dysmenorrhoea.
